当前位置: X-MOL 学术Prog. Lipid. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lipid-based biomarkers for CVD, COPD, and aging - A translational perspective.
Progress in Lipid Research ( IF 13.6 ) Pub Date : 2020-04-25 , DOI: 10.1016/j.plipres.2020.101030
Kim Ekroos 1 , Oksana Lavrynenko 2 , Bjoern Titz 2 , Calin Pater 2 , Julia Hoeng 2 , Nikolai V Ivanov 2
Affiliation  

For many diseases, there is an unmet need for new or better biomarkers for improved disease risk assessment and monitoring, as available markers lack sufficient specificity. Lipids are drawing major interest as potential candidates for filling these gaps. This has recently been demonstrated by the identification of selective ceramides for prediction of cardiovascular mortality, enabling improved risk assessment of cardiovascular disease compared with conventional clinical markers. In this review, we discuss current lipid biomarker findings and the possible connection between cardiovascular disease, chronic obstructive pulmonary disease, and aging. Moreover, we discuss how to overcome the current roadblocks facing lipid biomarker research. We stress the need for improved quantification, standardization of methodologies, and establishment of initial reference values to allow for an efficient transfer path of research findings into the clinical landscape, and, ultimately, to put newly identified biomarkers into practical use.



中文翻译:

用于CVD,COPD和老化的基于脂质的生物标记物-转化的视角。

对于许多疾病,由于可用的标记物缺乏足够的特异性,因此亟需新的或更好的生物标记物来改善疾病风险评估和监测。脂质作为填补这些空白的潜在候选者正引起人们的极大兴趣。最近已通过鉴定用于预测心血管疾病死亡率的选择性神经酰胺,证明了这一点,与传统的临床指标相比,可以改善心血管疾病的风险评估。在这篇综述中,我们讨论了当前脂质生物标志物的发现以及心血管疾病,慢性阻塞性肺疾病和衰老之间的可能联系。此外,我们讨论了如何克服脂质生物标志物研究面临的当前障碍。我们强调需要改进定量方法,标准化方法,

更新日期:2020-04-25
down
wechat
bug